Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.

home / news releases / TPTX - Blueprint Medicines Deciphera Black Diamond gain following Turning Point sale to Bristol Myers

TPTX - Blueprint Medicines Deciphera Black Diamond gain following Turning Point sale to Bristol Myers

Turning Point Therapeutics Inc.
Blueprint Medicines (NASDAQ:BPMC) rose 1.2% in premarket trading,  after Bristol Myers (BMY) agreed to acquire Turning Point Therapeutics (TPTX) for over $4B in cash. Stifel said in a note that buy-rated Blueprint (BPMC) came first to mind after Bristol agreed to buy TPTX. Bluelprint's BLU-945 and BLU-701 have similar development set-up as TPTX's repotrectinib. Another sympathy play may include hold-rated Deciphera Pharmaceuticals (NASDAQ:DCPH) and Black Diamond Therapeutics (NASDAQ:BDTX), according to Stifel analyst Bradley Canino. Deciphera (DCPH) rose 2.2% and Black Diamond (BDTX) gained 3%. Earlier Friday, Bristol Myers to acquire Turning Point Therapeutics for over $4B in cash.

For further details see:

Blueprint Medicines, Deciphera, Black Diamond gain following Turning Point sale to Bristol Myers
Stock Information
Company Name: Turning Point Therapeutics Inc.
Stock Symbol: TPTX
Market: NYSE
Website: tptherapeutics.com
Menu
TPTX TPTX Quote TPTX Short TPTX News TPTX Articles TPTX Message Board
Get TPTX Alerts

News, Short Squeeze, Breakout and More Instantly...